nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—BCHE—breast cancer	0.145	0.354	CbGaD
Mirabegron—CYP2D6—breast cancer	0.0796	0.194	CbGaD
Mirabegron—CYP3A4—breast cancer	0.0683	0.167	CbGaD
Mirabegron—SLCO1A2—Chlorambucil—breast cancer	0.0637	0.162	CbGbCtD
Mirabegron—ALB—breast cancer	0.0596	0.145	CbGaD
Mirabegron—ABCB1—breast cancer	0.0569	0.139	CbGaD
Mirabegron—BCHE—Irinotecan—breast cancer	0.0229	0.0584	CbGbCtD
Mirabegron—ABCB1—Toremifene—breast cancer	0.0208	0.0528	CbGbCtD
Mirabegron—CYP3A4—Exemestane—breast cancer	0.0179	0.0457	CbGbCtD
Mirabegron—CYP2D6—Idarubicin—breast cancer	0.0162	0.0412	CbGbCtD
Mirabegron—CYP3A4—Letrozole—breast cancer	0.0153	0.0388	CbGbCtD
Mirabegron—ABCB1—Lapatinib—breast cancer	0.0151	0.0385	CbGbCtD
Mirabegron—CYP3A4—Anastrozole—breast cancer	0.0136	0.0346	CbGbCtD
Mirabegron—CYP3A4—Toremifene—breast cancer	0.0124	0.0316	CbGbCtD
Mirabegron—CYP3A4—Fulvestrant—breast cancer	0.0116	0.0294	CbGbCtD
Mirabegron—SLCO1A2—Methotrexate—breast cancer	0.0114	0.029	CbGbCtD
Mirabegron—ALB—Irinotecan—breast cancer	0.0111	0.0283	CbGbCtD
Mirabegron—ALB—Fluorouracil—breast cancer	0.0107	0.0272	CbGbCtD
Mirabegron—CYP3A4—Thiotepa—breast cancer	0.0103	0.0262	CbGbCtD
Mirabegron—CYP3A4—Ixabepilone—breast cancer	0.00943	0.024	CbGbCtD
Mirabegron—CYP3A4—Lapatinib—breast cancer	0.00908	0.0231	CbGbCtD
Mirabegron—ABCB1—Vinorelbine—breast cancer	0.0084	0.0214	CbGbCtD
Mirabegron—CYP2D6—Vinorelbine—breast cancer	0.00792	0.0201	CbGbCtD
Mirabegron—ABCB1—Tamoxifen—breast cancer	0.00758	0.0193	CbGbCtD
Mirabegron—ABCB1—Mitoxantrone—breast cancer	0.0074	0.0188	CbGbCtD
Mirabegron—CYP2D6—Tamoxifen—breast cancer	0.00715	0.0182	CbGbCtD
Mirabegron—CYP3A4—Raloxifene—breast cancer	0.00688	0.0175	CbGbCtD
Mirabegron—ABCB1—Gemcitabine—breast cancer	0.00653	0.0166	CbGbCtD
Mirabegron—ABCB1—Paclitaxel—breast cancer	0.0059	0.015	CbGbCtD
Mirabegron—ALB—Methotrexate—breast cancer	0.00589	0.015	CbGbCtD
Mirabegron—ABCB1—Irinotecan—breast cancer	0.00582	0.0148	CbGbCtD
Mirabegron—ABCB1—Vinblastine—breast cancer	0.00518	0.0132	CbGbCtD
Mirabegron—CYP3A4—Vinorelbine—breast cancer	0.00503	0.0128	CbGbCtD
Mirabegron—CYP2D6—Vinblastine—breast cancer	0.00488	0.0124	CbGbCtD
Mirabegron—CYP3A4—Tamoxifen—breast cancer	0.00454	0.0116	CbGbCtD
Mirabegron—CYP3A4—Mitoxantrone—breast cancer	0.00443	0.0113	CbGbCtD
Mirabegron—ABCB1—Docetaxel—breast cancer	0.00427	0.0109	CbGbCtD
Mirabegron—CYP3A4—Paclitaxel—breast cancer	0.00354	0.009	CbGbCtD
Mirabegron—CYP3A4—Irinotecan—breast cancer	0.00349	0.00888	CbGbCtD
Mirabegron—ABCB1—Doxorubicin—breast cancer	0.00318	0.00809	CbGbCtD
Mirabegron—CYP3A4—Vinblastine—breast cancer	0.0031	0.00789	CbGbCtD
Mirabegron—ABCB1—Methotrexate—breast cancer	0.00308	0.00784	CbGbCtD
Mirabegron—CYP2D6—Doxorubicin—breast cancer	0.003	0.00763	CbGbCtD
Mirabegron—CYP3A4—Docetaxel—breast cancer	0.00256	0.0065	CbGbCtD
Mirabegron—CYP3A4—Doxorubicin—breast cancer	0.00191	0.00485	CbGbCtD
Mirabegron—ADRB3—adipose tissue—breast cancer	0.000598	0.0824	CbGeAlD
Mirabegron—ADRB3—female reproductive system—breast cancer	0.00055	0.0757	CbGeAlD
Mirabegron—ALB—mammary gland—breast cancer	0.00054	0.0744	CbGeAlD
Mirabegron—ADRB3—female gonad—breast cancer	0.0005	0.0689	CbGeAlD
Mirabegron—BCHE—nipple—breast cancer	0.000316	0.0435	CbGeAlD
Mirabegron—ORM1—endometrium—breast cancer	0.000308	0.0424	CbGeAlD
Mirabegron—ORM1—female reproductive system—breast cancer	0.000255	0.0351	CbGeAlD
Mirabegron—ORM1—bone marrow—breast cancer	0.000241	0.0332	CbGeAlD
Mirabegron—ALB—adrenal gland—breast cancer	0.000218	0.03	CbGeAlD
Mirabegron—ORM1—endocrine gland—breast cancer	0.000216	0.0297	CbGeAlD
Mirabegron—BCHE—skin of body—breast cancer	0.000202	0.0279	CbGeAlD
Mirabegron—BCHE—endometrium—breast cancer	0.000191	0.0263	CbGeAlD
Mirabegron—SLCO1A2—endocrine gland—breast cancer	0.00019	0.0262	CbGeAlD
Mirabegron—BCHE—uterus—breast cancer	0.000176	0.0242	CbGeAlD
Mirabegron—BCHE—pituitary gland—breast cancer	0.000173	0.0238	CbGeAlD
Mirabegron—BCHE—adipose tissue—breast cancer	0.000172	0.0237	CbGeAlD
Mirabegron—BCHE—female reproductive system—breast cancer	0.000158	0.0218	CbGeAlD
Mirabegron—BCHE—adrenal gland—breast cancer	0.000154	0.0212	CbGeAlD
Mirabegron—Labetalol—CYP2D6—breast cancer	0.000154	0.337	CrCbGaD
Mirabegron—BCHE—bone marrow—breast cancer	0.000149	0.0206	CbGeAlD
Mirabegron—ORM1—lymph node—breast cancer	0.000149	0.0205	CbGeAlD
Mirabegron—BCHE—endocrine gland—breast cancer	0.000134	0.0184	CbGeAlD
Mirabegron—ALB—lymph node—breast cancer	0.000131	0.018	CbGeAlD
Mirabegron—ABCB1—embryo—breast cancer	0.000124	0.0171	CbGeAlD
Mirabegron—Propafenone—CYP2D6—breast cancer	0.000117	0.258	CrCbGaD
Mirabegron—CYP3A4—female reproductive system—breast cancer	0.000106	0.0147	CbGeAlD
Mirabegron—CYP2D6—female reproductive system—breast cancer	0.000105	0.0144	CbGeAlD
Mirabegron—ABCB1—epithelium—breast cancer	0.000101	0.014	CbGeAlD
Mirabegron—Propafenone—CYP3A4—breast cancer	0.000101	0.221	CrCbGaD
Mirabegron—CYP2D6—female gonad—breast cancer	9.53e-05	0.0131	CbGeAlD
Mirabegron—BCHE—lymph node—breast cancer	9.25e-05	0.0127	CbGeAlD
Mirabegron—ABCB1—endometrium—breast cancer	9.09e-05	0.0125	CbGeAlD
Mirabegron—CYP3A4—endocrine gland—breast cancer	9e-05	0.0124	CbGeAlD
Mirabegron—CYP2D6—endocrine gland—breast cancer	8.86e-05	0.0122	CbGeAlD
Mirabegron—Propafenone—ABCB1—breast cancer	8.39e-05	0.184	CrCbGaD
Mirabegron—ABCB1—uterus—breast cancer	8.38e-05	0.0115	CbGeAlD
Mirabegron—ABCB1—pituitary gland—breast cancer	8.23e-05	0.0113	CbGeAlD
Mirabegron—ABCB1—adipose tissue—breast cancer	8.19e-05	0.0113	CbGeAlD
Mirabegron—Rash—Goserelin—breast cancer	7.92e-05	0.000598	CcSEcCtD
Mirabegron—Dermatitis—Goserelin—breast cancer	7.91e-05	0.000597	CcSEcCtD
Mirabegron—Arthralgia—Paclitaxel—breast cancer	7.89e-05	0.000596	CcSEcCtD
Mirabegron—Nasopharyngitis—Epirubicin—breast cancer	7.87e-05	0.000594	CcSEcCtD
Mirabegron—Headache—Goserelin—breast cancer	7.87e-05	0.000594	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	7.84e-05	0.000592	CcSEcCtD
Mirabegron—Dyspepsia—Fluorouracil—breast cancer	7.82e-05	0.000591	CcSEcCtD
Mirabegron—Nausea—Tamoxifen—breast cancer	7.81e-05	0.00059	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Gemcitabine—breast cancer	7.8e-05	0.000589	CcSEcCtD
Mirabegron—Fatigue—Gemcitabine—breast cancer	7.79e-05	0.000588	CcSEcCtD
Mirabegron—Gastritis—Epirubicin—breast cancer	7.79e-05	0.000588	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Epirubicin—breast cancer	7.76e-05	0.000586	CcSEcCtD
Mirabegron—Constipation—Gemcitabine—breast cancer	7.73e-05	0.000584	CcSEcCtD
Mirabegron—Dry mouth—Paclitaxel—breast cancer	7.72e-05	0.000583	CcSEcCtD
Mirabegron—Asthenia—Thiotepa—breast cancer	7.71e-05	0.000582	CcSEcCtD
Mirabegron—Diarrhoea—Vinorelbine—breast cancer	7.7e-05	0.000581	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Fluorouracil—breast cancer	7.67e-05	0.000579	CcSEcCtD
Mirabegron—Abdominal distension—Epirubicin—breast cancer	7.66e-05	0.000578	CcSEcCtD
Mirabegron—Nausea—Melphalan—breast cancer	7.65e-05	0.000577	CcSEcCtD
Mirabegron—Influenza—Epirubicin—breast cancer	7.61e-05	0.000574	CcSEcCtD
Mirabegron—Back pain—Docetaxel—breast cancer	7.6e-05	0.000574	CcSEcCtD
Mirabegron—Pruritus—Thiotepa—breast cancer	7.6e-05	0.000574	CcSEcCtD
Mirabegron—Gastrointestinal pain—Irinotecan—breast cancer	7.59e-05	0.000573	CcSEcCtD
Mirabegron—Gastrointestinal pain—Mitoxantrone—breast cancer	7.59e-05	0.000573	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Methotrexate—breast cancer	7.56e-05	0.00057	CcSEcCtD
Mirabegron—ABCB1—female reproductive system—breast cancer	7.53e-05	0.0104	CbGeAlD
Mirabegron—Infection—Paclitaxel—breast cancer	7.52e-05	0.000568	CcSEcCtD
Mirabegron—Nausea—Goserelin—breast cancer	7.46e-05	0.000563	CcSEcCtD
Mirabegron—Dizziness—Vinorelbine—breast cancer	7.44e-05	0.000562	CcSEcCtD
Mirabegron—Tachycardia—Paclitaxel—breast cancer	7.39e-05	0.000558	CcSEcCtD
Mirabegron—Urticaria—Mitoxantrone—breast cancer	7.37e-05	0.000556	CcSEcCtD
Mirabegron—Back pain—Capecitabine—breast cancer	7.36e-05	0.000556	CcSEcCtD
Mirabegron—Breast disorder—Doxorubicin—breast cancer	7.36e-05	0.000556	CcSEcCtD
Mirabegron—Diarrhoea—Thiotepa—breast cancer	7.35e-05	0.000555	CcSEcCtD
Mirabegron—Skin disorder—Paclitaxel—breast cancer	7.35e-05	0.000555	CcSEcCtD
Mirabegron—ABCB1—adrenal gland—breast cancer	7.35e-05	0.0101	CbGeAlD
Mirabegron—Abdominal pain—Irinotecan—breast cancer	7.34e-05	0.000554	CcSEcCtD
Mirabegron—Abdominal pain—Mitoxantrone—breast cancer	7.34e-05	0.000554	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Doxorubicin—breast cancer	7.33e-05	0.000554	CcSEcCtD
Mirabegron—Nasopharyngitis—Doxorubicin—breast cancer	7.28e-05	0.00055	CcSEcCtD
Mirabegron—Infestation NOS—Methotrexate—breast cancer	7.25e-05	0.000547	CcSEcCtD
Mirabegron—Infestation—Methotrexate—breast cancer	7.25e-05	0.000547	CcSEcCtD
Mirabegron—Gastritis—Doxorubicin—breast cancer	7.21e-05	0.000544	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Methotrexate—breast cancer	7.19e-05	0.000543	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Doxorubicin—breast cancer	7.18e-05	0.000542	CcSEcCtD
Mirabegron—Vision blurred—Capecitabine—breast cancer	7.17e-05	0.000541	CcSEcCtD
Mirabegron—ABCB1—bone marrow—breast cancer	7.11e-05	0.0098	CbGeAlD
Mirabegron—Dizziness—Thiotepa—breast cancer	7.11e-05	0.000536	CcSEcCtD
Mirabegron—Rash—Vinorelbine—breast cancer	7.09e-05	0.000536	CcSEcCtD
Mirabegron—Dermatitis—Vinorelbine—breast cancer	7.09e-05	0.000535	CcSEcCtD
Mirabegron—Abdominal distension—Doxorubicin—breast cancer	7.09e-05	0.000535	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Epirubicin—breast cancer	7.07e-05	0.000534	CcSEcCtD
Mirabegron—Urticaria—Fluorouracil—breast cancer	7.06e-05	0.000533	CcSEcCtD
Mirabegron—Headache—Vinorelbine—breast cancer	7.05e-05	0.000532	CcSEcCtD
Mirabegron—Influenza—Doxorubicin—breast cancer	7.04e-05	0.000531	CcSEcCtD
Mirabegron—Palpitations—Docetaxel—breast cancer	6.95e-05	0.000524	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Paclitaxel—breast cancer	6.89e-05	0.000521	CcSEcCtD
Mirabegron—ABCB1—female gonad—breast cancer	6.85e-05	0.00944	CbGeAlD
Mirabegron—Hypertension—Docetaxel—breast cancer	6.79e-05	0.000512	CcSEcCtD
Mirabegron—Infestation NOS—Epirubicin—breast cancer	6.78e-05	0.000512	CcSEcCtD
Mirabegron—Infestation—Epirubicin—breast cancer	6.78e-05	0.000512	CcSEcCtD
Mirabegron—Rash—Thiotepa—breast cancer	6.78e-05	0.000511	CcSEcCtD
Mirabegron—Dermatitis—Thiotepa—breast cancer	6.77e-05	0.000511	CcSEcCtD
Mirabegron—Headache—Thiotepa—breast cancer	6.73e-05	0.000508	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Epirubicin—breast cancer	6.73e-05	0.000508	CcSEcCtD
Mirabegron—Palpitations—Capecitabine—breast cancer	6.72e-05	0.000508	CcSEcCtD
Mirabegron—Arthralgia—Docetaxel—breast cancer	6.69e-05	0.000505	CcSEcCtD
Mirabegron—Nausea—Vinorelbine—breast cancer	6.68e-05	0.000505	CcSEcCtD
Mirabegron—Dyspepsia—Paclitaxel—breast cancer	6.66e-05	0.000503	CcSEcCtD
Mirabegron—Asthenia—Mitoxantrone—breast cancer	6.66e-05	0.000503	CcSEcCtD
Mirabegron—Asthenia—Irinotecan—breast cancer	6.66e-05	0.000503	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	6.65e-05	0.000502	CcSEcCtD
Mirabegron—Urinary tract infection—Epirubicin—breast cancer	6.59e-05	0.000498	CcSEcCtD
Mirabegron—Hypertension—Capecitabine—breast cancer	6.57e-05	0.000496	CcSEcCtD
Mirabegron—Dry mouth—Docetaxel—breast cancer	6.54e-05	0.000494	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Doxorubicin—breast cancer	6.54e-05	0.000494	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Paclitaxel—breast cancer	6.53e-05	0.000493	CcSEcCtD
Mirabegron—Fatigue—Paclitaxel—breast cancer	6.52e-05	0.000493	CcSEcCtD
Mirabegron—Asthenia—Gemcitabine—breast cancer	6.49e-05	0.00049	CcSEcCtD
Mirabegron—Arthralgia—Capecitabine—breast cancer	6.48e-05	0.000489	CcSEcCtD
Mirabegron—Constipation—Paclitaxel—breast cancer	6.47e-05	0.000489	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	6.43e-05	0.000486	CcSEcCtD
Mirabegron—Urinary tract disorder—Methotrexate—breast cancer	6.43e-05	0.000485	CcSEcCtD
Mirabegron—Pruritus—Gemcitabine—breast cancer	6.4e-05	0.000483	CcSEcCtD
Mirabegron—Nausea—Thiotepa—breast cancer	6.38e-05	0.000482	CcSEcCtD
Mirabegron—Urethral disorder—Methotrexate—breast cancer	6.38e-05	0.000482	CcSEcCtD
Mirabegron—ABCB1—endocrine gland—breast cancer	6.37e-05	0.00878	CbGeAlD
Mirabegron—Infection—Docetaxel—breast cancer	6.37e-05	0.000481	CcSEcCtD
Mirabegron—Sinusitis—Epirubicin—breast cancer	6.36e-05	0.00048	CcSEcCtD
Mirabegron—Diarrhoea—Irinotecan—breast cancer	6.35e-05	0.000479	CcSEcCtD
Mirabegron—Diarrhoea—Mitoxantrone—breast cancer	6.35e-05	0.000479	CcSEcCtD
Mirabegron—Dry mouth—Capecitabine—breast cancer	6.34e-05	0.000478	CcSEcCtD
Mirabegron—Pruritus—Fluorouracil—breast cancer	6.29e-05	0.000475	CcSEcCtD
Mirabegron—Infestation NOS—Doxorubicin—breast cancer	6.28e-05	0.000474	CcSEcCtD
Mirabegron—Infestation—Doxorubicin—breast cancer	6.28e-05	0.000474	CcSEcCtD
Mirabegron—Tachycardia—Docetaxel—breast cancer	6.26e-05	0.000473	CcSEcCtD
Mirabegron—Skin disorder—Docetaxel—breast cancer	6.23e-05	0.00047	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Doxorubicin—breast cancer	6.22e-05	0.00047	CcSEcCtD
Mirabegron—Gastrointestinal pain—Paclitaxel—breast cancer	6.19e-05	0.000467	CcSEcCtD
Mirabegron—Diarrhoea—Gemcitabine—breast cancer	6.18e-05	0.000467	CcSEcCtD
Mirabegron—Infection—Capecitabine—breast cancer	6.17e-05	0.000466	CcSEcCtD
Mirabegron—Erythema multiforme—Methotrexate—breast cancer	6.15e-05	0.000464	CcSEcCtD
Mirabegron—Dizziness—Irinotecan—breast cancer	6.14e-05	0.000463	CcSEcCtD
Mirabegron—Rhinitis—Epirubicin—breast cancer	6.11e-05	0.000461	CcSEcCtD
Mirabegron—Urinary tract infection—Doxorubicin—breast cancer	6.1e-05	0.000461	CcSEcCtD
Mirabegron—Eye disorder—Methotrexate—breast cancer	6.08e-05	0.000459	CcSEcCtD
Mirabegron—Diarrhoea—Fluorouracil—breast cancer	6.08e-05	0.000459	CcSEcCtD
Mirabegron—Tachycardia—Capecitabine—breast cancer	6.06e-05	0.000458	CcSEcCtD
Mirabegron—Cardiac disorder—Methotrexate—breast cancer	6.04e-05	0.000456	CcSEcCtD
Mirabegron—Skin disorder—Capecitabine—breast cancer	6.03e-05	0.000455	CcSEcCtD
Mirabegron—Urinary tract disorder—Epirubicin—breast cancer	6.01e-05	0.000454	CcSEcCtD
Mirabegron—Urticaria—Paclitaxel—breast cancer	6.01e-05	0.000454	CcSEcCtD
Mirabegron—Connective tissue disorder—Epirubicin—breast cancer	5.98e-05	0.000452	CcSEcCtD
Mirabegron—Abdominal pain—Paclitaxel—breast cancer	5.98e-05	0.000452	CcSEcCtD
Mirabegron—Urethral disorder—Epirubicin—breast cancer	5.97e-05	0.000451	CcSEcCtD
Mirabegron—Sinusitis—Doxorubicin—breast cancer	5.89e-05	0.000445	CcSEcCtD
Mirabegron—Dizziness—Fluorouracil—breast cancer	5.88e-05	0.000444	CcSEcCtD
Mirabegron—Rash—Irinotecan—breast cancer	5.85e-05	0.000442	CcSEcCtD
Mirabegron—Rash—Mitoxantrone—breast cancer	5.85e-05	0.000442	CcSEcCtD
Mirabegron—Dermatitis—Irinotecan—breast cancer	5.85e-05	0.000441	CcSEcCtD
Mirabegron—Dermatitis—Mitoxantrone—breast cancer	5.85e-05	0.000441	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Docetaxel—breast cancer	5.84e-05	0.000441	CcSEcCtD
Mirabegron—Headache—Mitoxantrone—breast cancer	5.81e-05	0.000439	CcSEcCtD
Mirabegron—Headache—Irinotecan—breast cancer	5.81e-05	0.000439	CcSEcCtD
Mirabegron—Erythema multiforme—Epirubicin—breast cancer	5.76e-05	0.000435	CcSEcCtD
Mirabegron—Rash—Gemcitabine—breast cancer	5.7e-05	0.00043	CcSEcCtD
Mirabegron—Dermatitis—Gemcitabine—breast cancer	5.69e-05	0.00043	CcSEcCtD
Mirabegron—Eye disorder—Epirubicin—breast cancer	5.69e-05	0.00043	CcSEcCtD
Mirabegron—Headache—Gemcitabine—breast cancer	5.66e-05	0.000427	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Capecitabine—breast cancer	5.66e-05	0.000427	CcSEcCtD
Mirabegron—Cardiac disorder—Epirubicin—breast cancer	5.65e-05	0.000427	CcSEcCtD
Mirabegron—Rhinitis—Doxorubicin—breast cancer	5.65e-05	0.000426	CcSEcCtD
Mirabegron—Dyspepsia—Docetaxel—breast cancer	5.65e-05	0.000426	CcSEcCtD
Mirabegron—Rash—Fluorouracil—breast cancer	5.6e-05	0.000423	CcSEcCtD
Mirabegron—Dermatitis—Fluorouracil—breast cancer	5.6e-05	0.000423	CcSEcCtD
Mirabegron—Headache—Fluorouracil—breast cancer	5.57e-05	0.00042	CcSEcCtD
Mirabegron—Urinary tract disorder—Doxorubicin—breast cancer	5.56e-05	0.00042	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Docetaxel—breast cancer	5.54e-05	0.000418	CcSEcCtD
Mirabegron—Connective tissue disorder—Doxorubicin—breast cancer	5.54e-05	0.000418	CcSEcCtD
Mirabegron—Fatigue—Docetaxel—breast cancer	5.53e-05	0.000417	CcSEcCtD
Mirabegron—Urethral disorder—Doxorubicin—breast cancer	5.52e-05	0.000417	CcSEcCtD
Mirabegron—Nausea—Irinotecan—breast cancer	5.51e-05	0.000416	CcSEcCtD
Mirabegron—Nausea—Mitoxantrone—breast cancer	5.51e-05	0.000416	CcSEcCtD
Mirabegron—Constipation—Docetaxel—breast cancer	5.49e-05	0.000414	CcSEcCtD
Mirabegron—Back pain—Methotrexate—breast cancer	5.48e-05	0.000414	CcSEcCtD
Mirabegron—Dyspepsia—Capecitabine—breast cancer	5.47e-05	0.000413	CcSEcCtD
Mirabegron—Asthenia—Paclitaxel—breast cancer	5.43e-05	0.00041	CcSEcCtD
Mirabegron—Nausea—Gemcitabine—breast cancer	5.37e-05	0.000405	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Capecitabine—breast cancer	5.36e-05	0.000405	CcSEcCtD
Mirabegron—Fatigue—Capecitabine—breast cancer	5.35e-05	0.000404	CcSEcCtD
Mirabegron—Pruritus—Paclitaxel—breast cancer	5.35e-05	0.000404	CcSEcCtD
Mirabegron—Vision blurred—Methotrexate—breast cancer	5.34e-05	0.000403	CcSEcCtD
Mirabegron—Erythema multiforme—Doxorubicin—breast cancer	5.33e-05	0.000402	CcSEcCtD
Mirabegron—Constipation—Capecitabine—breast cancer	5.31e-05	0.000401	CcSEcCtD
Mirabegron—Nausea—Fluorouracil—breast cancer	5.28e-05	0.000399	CcSEcCtD
Mirabegron—Eye disorder—Doxorubicin—breast cancer	5.27e-05	0.000398	CcSEcCtD
Mirabegron—Gastrointestinal pain—Docetaxel—breast cancer	5.25e-05	0.000396	CcSEcCtD
Mirabegron—Cardiac disorder—Doxorubicin—breast cancer	5.23e-05	0.000395	CcSEcCtD
Mirabegron—Diarrhoea—Paclitaxel—breast cancer	5.18e-05	0.000391	CcSEcCtD
Mirabegron—Back pain—Epirubicin—breast cancer	5.13e-05	0.000387	CcSEcCtD
Mirabegron—Gastrointestinal pain—Capecitabine—breast cancer	5.08e-05	0.000383	CcSEcCtD
Mirabegron—Abdominal pain—Docetaxel—breast cancer	5.07e-05	0.000383	CcSEcCtD
Mirabegron—Dizziness—Paclitaxel—breast cancer	5e-05	0.000378	CcSEcCtD
Mirabegron—Vision blurred—Epirubicin—breast cancer	5e-05	0.000377	CcSEcCtD
Mirabegron—Urticaria—Capecitabine—breast cancer	4.93e-05	0.000372	CcSEcCtD
Mirabegron—Abdominal pain—Capecitabine—breast cancer	4.91e-05	0.000371	CcSEcCtD
Mirabegron—Arthralgia—Methotrexate—breast cancer	4.82e-05	0.000364	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.79e-05	0.000362	CcSEcCtD
Mirabegron—Rash—Paclitaxel—breast cancer	4.77e-05	0.00036	CcSEcCtD
Mirabegron—Dermatitis—Paclitaxel—breast cancer	4.77e-05	0.00036	CcSEcCtD
Mirabegron—Back pain—Doxorubicin—breast cancer	4.74e-05	0.000358	CcSEcCtD
Mirabegron—Headache—Paclitaxel—breast cancer	4.74e-05	0.000358	CcSEcCtD
Mirabegron—Palpitations—Epirubicin—breast cancer	4.68e-05	0.000354	CcSEcCtD
Mirabegron—Vision blurred—Doxorubicin—breast cancer	4.62e-05	0.000349	CcSEcCtD
Mirabegron—Asthenia—Docetaxel—breast cancer	4.6e-05	0.000347	CcSEcCtD
Mirabegron—Infection—Methotrexate—breast cancer	4.59e-05	0.000347	CcSEcCtD
Mirabegron—Hypertension—Epirubicin—breast cancer	4.58e-05	0.000346	CcSEcCtD
Mirabegron—Pruritus—Docetaxel—breast cancer	4.54e-05	0.000343	CcSEcCtD
Mirabegron—Arthralgia—Epirubicin—breast cancer	4.51e-05	0.000341	CcSEcCtD
Mirabegron—Nausea—Paclitaxel—breast cancer	4.5e-05	0.000339	CcSEcCtD
Mirabegron—Skin disorder—Methotrexate—breast cancer	4.49e-05	0.000339	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	4.48e-05	0.000338	CcSEcCtD
Mirabegron—Asthenia—Capecitabine—breast cancer	4.46e-05	0.000336	CcSEcCtD
Mirabegron—Dry mouth—Epirubicin—breast cancer	4.41e-05	0.000333	CcSEcCtD
Mirabegron—ABCB1—lymph node—breast cancer	4.41e-05	0.00607	CbGeAlD
Mirabegron—Pruritus—Capecitabine—breast cancer	4.39e-05	0.000332	CcSEcCtD
Mirabegron—Diarrhoea—Docetaxel—breast cancer	4.39e-05	0.000331	CcSEcCtD
Mirabegron—Palpitations—Doxorubicin—breast cancer	4.33e-05	0.000327	CcSEcCtD
Mirabegron—Infection—Epirubicin—breast cancer	4.3e-05	0.000324	CcSEcCtD
Mirabegron—Diarrhoea—Capecitabine—breast cancer	4.25e-05	0.000321	CcSEcCtD
Mirabegron—Dizziness—Docetaxel—breast cancer	4.24e-05	0.00032	CcSEcCtD
Mirabegron—Hypertension—Doxorubicin—breast cancer	4.23e-05	0.00032	CcSEcCtD
Mirabegron—Tachycardia—Epirubicin—breast cancer	4.22e-05	0.000319	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methotrexate—breast cancer	4.21e-05	0.000318	CcSEcCtD
Mirabegron—Skin disorder—Epirubicin—breast cancer	4.2e-05	0.000317	CcSEcCtD
Mirabegron—Arthralgia—Doxorubicin—breast cancer	4.18e-05	0.000315	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	4.15e-05	0.000313	CcSEcCtD
Mirabegron—Dizziness—Capecitabine—breast cancer	4.11e-05	0.00031	CcSEcCtD
Mirabegron—Dry mouth—Doxorubicin—breast cancer	4.08e-05	0.000308	CcSEcCtD
Mirabegron—Dyspepsia—Methotrexate—breast cancer	4.07e-05	0.000307	CcSEcCtD
Mirabegron—Rash—Docetaxel—breast cancer	4.04e-05	0.000305	CcSEcCtD
Mirabegron—Dermatitis—Docetaxel—breast cancer	4.04e-05	0.000305	CcSEcCtD
Mirabegron—Headache—Docetaxel—breast cancer	4.02e-05	0.000303	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Methotrexate—breast cancer	3.99e-05	0.000301	CcSEcCtD
Mirabegron—Fatigue—Methotrexate—breast cancer	3.99e-05	0.000301	CcSEcCtD
Mirabegron—Infection—Doxorubicin—breast cancer	3.98e-05	0.0003	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Epirubicin—breast cancer	3.94e-05	0.000298	CcSEcCtD
Mirabegron—Rash—Capecitabine—breast cancer	3.92e-05	0.000296	CcSEcCtD
Mirabegron—Dermatitis—Capecitabine—breast cancer	3.91e-05	0.000295	CcSEcCtD
Mirabegron—Tachycardia—Doxorubicin—breast cancer	3.91e-05	0.000295	CcSEcCtD
Mirabegron—Headache—Capecitabine—breast cancer	3.89e-05	0.000294	CcSEcCtD
Mirabegron—Skin disorder—Doxorubicin—breast cancer	3.89e-05	0.000294	CcSEcCtD
Mirabegron—Nausea—Docetaxel—breast cancer	3.81e-05	0.000288	CcSEcCtD
Mirabegron—Dyspepsia—Epirubicin—breast cancer	3.81e-05	0.000288	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methotrexate—breast cancer	3.78e-05	0.000285	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Epirubicin—breast cancer	3.74e-05	0.000282	CcSEcCtD
Mirabegron—Fatigue—Epirubicin—breast cancer	3.73e-05	0.000282	CcSEcCtD
Mirabegron—Constipation—Epirubicin—breast cancer	3.7e-05	0.000279	CcSEcCtD
Mirabegron—Nausea—Capecitabine—breast cancer	3.69e-05	0.000278	CcSEcCtD
Mirabegron—Urticaria—Methotrexate—breast cancer	3.67e-05	0.000277	CcSEcCtD
Mirabegron—Abdominal pain—Methotrexate—breast cancer	3.65e-05	0.000276	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.65e-05	0.000275	CcSEcCtD
Mirabegron—Gastrointestinal pain—Epirubicin—breast cancer	3.54e-05	0.000267	CcSEcCtD
Mirabegron—Dyspepsia—Doxorubicin—breast cancer	3.52e-05	0.000266	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Doxorubicin—breast cancer	3.46e-05	0.000261	CcSEcCtD
Mirabegron—Fatigue—Doxorubicin—breast cancer	3.45e-05	0.000261	CcSEcCtD
Mirabegron—Urticaria—Epirubicin—breast cancer	3.44e-05	0.000259	CcSEcCtD
Mirabegron—Constipation—Doxorubicin—breast cancer	3.42e-05	0.000258	CcSEcCtD
Mirabegron—Abdominal pain—Epirubicin—breast cancer	3.42e-05	0.000258	CcSEcCtD
Mirabegron—Asthenia—Methotrexate—breast cancer	3.32e-05	0.00025	CcSEcCtD
Mirabegron—Gastrointestinal pain—Doxorubicin—breast cancer	3.27e-05	0.000247	CcSEcCtD
Mirabegron—Pruritus—Methotrexate—breast cancer	3.27e-05	0.000247	CcSEcCtD
Mirabegron—Urticaria—Doxorubicin—breast cancer	3.18e-05	0.00024	CcSEcCtD
Mirabegron—Abdominal pain—Doxorubicin—breast cancer	3.16e-05	0.000239	CcSEcCtD
Mirabegron—Diarrhoea—Methotrexate—breast cancer	3.16e-05	0.000239	CcSEcCtD
Mirabegron—Asthenia—Epirubicin—breast cancer	3.1e-05	0.000234	CcSEcCtD
Mirabegron—Pruritus—Epirubicin—breast cancer	3.06e-05	0.000231	CcSEcCtD
Mirabegron—Dizziness—Methotrexate—breast cancer	3.06e-05	0.000231	CcSEcCtD
Mirabegron—Diarrhoea—Epirubicin—breast cancer	2.96e-05	0.000223	CcSEcCtD
Mirabegron—Rash—Methotrexate—breast cancer	2.92e-05	0.00022	CcSEcCtD
Mirabegron—Dermatitis—Methotrexate—breast cancer	2.91e-05	0.00022	CcSEcCtD
Mirabegron—Headache—Methotrexate—breast cancer	2.9e-05	0.000219	CcSEcCtD
Mirabegron—Asthenia—Doxorubicin—breast cancer	2.87e-05	0.000217	CcSEcCtD
Mirabegron—Dizziness—Epirubicin—breast cancer	2.86e-05	0.000216	CcSEcCtD
Mirabegron—Pruritus—Doxorubicin—breast cancer	2.83e-05	0.000214	CcSEcCtD
Mirabegron—Nausea—Methotrexate—breast cancer	2.75e-05	0.000207	CcSEcCtD
Mirabegron—Diarrhoea—Doxorubicin—breast cancer	2.74e-05	0.000207	CcSEcCtD
Mirabegron—Rash—Epirubicin—breast cancer	2.73e-05	0.000206	CcSEcCtD
Mirabegron—Dermatitis—Epirubicin—breast cancer	2.73e-05	0.000206	CcSEcCtD
Mirabegron—Headache—Epirubicin—breast cancer	2.71e-05	0.000205	CcSEcCtD
Mirabegron—Dizziness—Doxorubicin—breast cancer	2.65e-05	0.0002	CcSEcCtD
Mirabegron—Nausea—Epirubicin—breast cancer	2.57e-05	0.000194	CcSEcCtD
Mirabegron—Rash—Doxorubicin—breast cancer	2.52e-05	0.000191	CcSEcCtD
Mirabegron—Dermatitis—Doxorubicin—breast cancer	2.52e-05	0.00019	CcSEcCtD
Mirabegron—Headache—Doxorubicin—breast cancer	2.51e-05	0.000189	CcSEcCtD
Mirabegron—Nausea—Doxorubicin—breast cancer	2.38e-05	0.00018	CcSEcCtD
Mirabegron—ABCB1—Metabolism—GSTT1—breast cancer	4.86e-06	8.5e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—FASN—breast cancer	4.86e-06	8.49e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ERBB2—breast cancer	4.84e-06	8.46e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—BCHE—breast cancer	4.84e-06	8.46e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CPT1A—breast cancer	4.82e-06	8.43e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ABCG2—breast cancer	4.82e-06	8.43e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—MTR—breast cancer	4.82e-06	8.43e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—LDHB—breast cancer	4.79e-06	8.38e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HPSE—breast cancer	4.79e-06	8.38e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—BRIP1—breast cancer	4.79e-06	8.38e-05	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	4.79e-06	8.38e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MTOR—breast cancer	4.78e-06	8.35e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CB—breast cancer	4.78e-06	8.35e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SLC5A5—breast cancer	4.78e-06	8.35e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—HPGDS—breast cancer	4.73e-06	8.26e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CD—breast cancer	4.72e-06	8.26e-05	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	4.72e-06	8.25e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CG—breast cancer	4.71e-06	8.24e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—HBA1—breast cancer	4.7e-06	8.21e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ALB—breast cancer	4.66e-06	8.15e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NQO1—breast cancer	4.61e-06	8.07e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SLC2A1—breast cancer	4.61e-06	8.07e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP17A1—breast cancer	4.6e-06	8.05e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCL8—breast cancer	4.59e-06	8.03e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTT1—breast cancer	4.58e-06	8.01e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ACHE—breast cancer	4.58e-06	8.01e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—HRAS—breast cancer	4.56e-06	7.97e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ENO1—breast cancer	4.56e-06	7.97e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTGS1—breast cancer	4.56e-06	7.97e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IL2—breast cancer	4.56e-06	7.97e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTA3—breast cancer	4.54e-06	7.95e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HMMR—breast cancer	4.54e-06	7.95e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ABCC1—breast cancer	4.54e-06	7.95e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.52e-06	7.9e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP3A4—breast cancer	4.5e-06	7.87e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN1B—breast cancer	4.48e-06	7.84e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	4.48e-06	7.83e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP2D6—breast cancer	4.47e-06	7.81e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—NOS3—breast cancer	4.46e-06	7.8e-05	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—AKT1—breast cancer	4.43e-06	7.75e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP1B1—breast cancer	4.42e-06	7.73e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PPARGC1B—breast cancer	4.4e-06	7.7e-05	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	4.4e-06	7.69e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CASP3—breast cancer	4.39e-06	7.68e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NCOA2—breast cancer	4.39e-06	7.67e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL2—breast cancer	4.39e-06	7.67e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL6—breast cancer	4.36e-06	7.63e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP17A1—breast cancer	4.34e-06	7.59e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—HSP90AA1—breast cancer	4.34e-06	7.58e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ENO1—breast cancer	4.29e-06	7.51e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTGS1—breast cancer	4.29e-06	7.51e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCND1—breast cancer	4.28e-06	7.48e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—JUN—breast cancer	4.27e-06	7.46e-05	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	4.26e-06	7.45e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—FASN—breast cancer	4.25e-06	7.44e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—BCHE—breast cancer	4.24e-06	7.41e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CTNNB1—breast cancer	4.23e-06	7.4e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NCOA1—breast cancer	4.22e-06	7.38e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC5A5—breast cancer	4.18e-06	7.32e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—STK11—breast cancer	4.16e-06	7.27e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP19A1—breast cancer	4.16e-06	7.27e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CA9—breast cancer	4.16e-06	7.27e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTA4—breast cancer	4.16e-06	7.27e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MMP9—breast cancer	4.15e-06	7.26e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CD—breast cancer	4.14e-06	7.25e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN1A—breast cancer	4.14e-06	7.23e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOA2—breast cancer	4.13e-06	7.23e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTEN—breast cancer	4.13e-06	7.22e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CB—breast cancer	4.12e-06	7.2e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ALB—breast cancer	4.09e-06	7.15e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTGS2—breast cancer	4.08e-06	7.13e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTA2—breast cancer	4.05e-06	7.08e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GPX2—breast cancer	4.05e-06	7.08e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NQO1—breast cancer	4.04e-06	7.07e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC2A1—breast cancer	4.04e-06	7.07e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MAPK8—breast cancer	4.04e-06	7.06e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—AKT1—breast cancer	4.03e-06	7.04e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—FASN—breast cancer	4.01e-06	7.01e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SULT1A1—breast cancer	4e-06	7e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GPX4—breast cancer	4e-06	7e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—BCHE—breast cancer	3.99e-06	6.98e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SRC—breast cancer	3.98e-06	6.95e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC5A5—breast cancer	3.94e-06	6.9e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP3A4—breast cancer	3.94e-06	6.89e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—NOS3—breast cancer	3.91e-06	6.84e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—IDH1—breast cancer	3.91e-06	6.83e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTA1—breast cancer	3.91e-06	6.83e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.9e-06	6.83e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP1B1—breast cancer	3.87e-06	6.78e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—VEGFA—breast cancer	3.87e-06	6.77e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—COMT—breast cancer	3.87e-06	6.76e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NAT2—breast cancer	3.86e-06	6.76e-05	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	3.85e-06	6.74e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTP1—breast cancer	3.85e-06	6.73e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SRC—breast cancer	3.83e-06	6.69e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC2A1—breast cancer	3.81e-06	6.66e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NQO1—breast cancer	3.81e-06	6.66e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—HSP90AA1—breast cancer	3.8e-06	6.64e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—HMOX1—breast cancer	3.79e-06	6.63e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ITPR1—breast cancer	3.79e-06	6.62e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—VEGFA—breast cancer	3.73e-06	6.52e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP3A4—breast cancer	3.71e-06	6.49e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NCOA1—breast cancer	3.7e-06	6.46e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—STAT3—breast cancer	3.69e-06	6.45e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—MAPK3—breast cancer	3.66e-06	6.41e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP1B1—breast cancer	3.65e-06	6.39e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—STK11—breast cancer	3.64e-06	6.37e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP19A1—breast cancer	3.64e-06	6.37e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ABCB1—breast cancer	3.64e-06	6.37e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CB—breast cancer	3.61e-06	6.32e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—HSP90AA1—breast cancer	3.58e-06	6.26e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTGS2—breast cancer	3.58e-06	6.26e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—TYMS—breast cancer	3.58e-06	6.25e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTEN—breast cancer	3.56e-06	6.22e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TGFB1—breast cancer	3.55e-06	6.21e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTM1—breast cancer	3.54e-06	6.18e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PLA2G4A—breast cancer	3.54e-06	6.18e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NCOR1—breast cancer	3.54e-06	6.18e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MAPK3—breast cancer	3.53e-06	6.17e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOA1—breast cancer	3.48e-06	6.09e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—STK11—breast cancer	3.43e-06	6e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP19A1—breast cancer	3.43e-06	6e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MYC—breast cancer	3.43e-06	6e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TGFB1—breast cancer	3.42e-06	5.98e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MED12—breast cancer	3.39e-06	5.93e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—DPYD—breast cancer	3.39e-06	5.93e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—COMT—breast cancer	3.39e-06	5.92e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GPX1—breast cancer	3.39e-06	5.92e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTP1—breast cancer	3.37e-06	5.89e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EGFR—breast cancer	3.35e-06	5.87e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP1A1—breast cancer	3.35e-06	5.86e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALDOA—breast cancer	3.34e-06	5.83e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—HMOX1—breast cancer	3.32e-06	5.81e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ERCC2—breast cancer	3.32e-06	5.81e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ITPR1—breast cancer	3.32e-06	5.8e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—KRAS—breast cancer	3.29e-06	5.76e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOA3—breast cancer	3.24e-06	5.66e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC2A2—breast cancer	3.22e-06	5.62e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—COMT—breast cancer	3.19e-06	5.58e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTP1—breast cancer	3.18e-06	5.55e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KRAS—breast cancer	3.17e-06	5.54e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ABCG2—breast cancer	3.15e-06	5.51e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CPT1A—breast cancer	3.15e-06	5.51e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MTR—breast cancer	3.15e-06	5.51e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—TYMS—breast cancer	3.13e-06	5.48e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—HMOX1—breast cancer	3.13e-06	5.48e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ITPR1—breast cancer	3.13e-06	5.47e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—MTHFR—breast cancer	3.12e-06	5.46e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTEN—breast cancer	3.12e-06	5.46e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PLA2G4A—breast cancer	3.1e-06	5.42e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTM1—breast cancer	3.1e-06	5.42e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NCOR1—breast cancer	3.1e-06	5.42e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HPGDS—breast cancer	3.09e-06	5.4e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HBA1—breast cancer	3.07e-06	5.37e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CA—breast cancer	3.02e-06	5.29e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ABCB1—breast cancer	3.01e-06	5.26e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTT1—breast cancer	3e-06	5.24e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ACHE—breast cancer	3e-06	5.24e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GPX1—breast cancer	2.97e-06	5.19e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TYMS—breast cancer	2.95e-06	5.16e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP1A1—breast cancer	2.94e-06	5.14e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TP53—breast cancer	2.93e-06	5.12e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PLA2G4A—breast cancer	2.92e-06	5.1e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTM1—breast cancer	2.92e-06	5.1e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOR1—breast cancer	2.92e-06	5.1e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ERCC2—breast cancer	2.91e-06	5.09e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CA—breast cancer	2.91e-06	5.09e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CAV1—breast cancer	2.88e-06	5.04e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP17A1—breast cancer	2.84e-06	4.96e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TP53—breast cancer	2.82e-06	4.93e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ENO1—breast cancer	2.81e-06	4.91e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTGS1—breast cancer	2.81e-06	4.91e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—HRAS—breast cancer	2.8e-06	4.89e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GPX1—breast cancer	2.8e-06	4.89e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP1A1—breast cancer	2.77e-06	4.84e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.75e-06	4.81e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP2D6—breast cancer	2.75e-06	4.81e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ERCC2—breast cancer	2.74e-06	4.8e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—MTHFR—breast cancer	2.74e-06	4.79e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOA2—breast cancer	2.7e-06	4.73e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HRAS—breast cancer	2.69e-06	4.71e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CG—breast cancer	2.63e-06	4.59e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—FASN—breast cancer	2.62e-06	4.58e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—BCHE—breast cancer	2.61e-06	4.56e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—MTHFR—breast cancer	2.58e-06	4.51e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL6—breast cancer	2.58e-06	4.51e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC5A5—breast cancer	2.58e-06	4.51e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CAV1—breast cancer	2.53e-06	4.42e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CA—breast cancer	2.51e-06	4.39e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC2A1—breast cancer	2.49e-06	4.35e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NQO1—breast cancer	2.49e-06	4.35e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—AKT1—breast cancer	2.47e-06	4.32e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP1B1—breast cancer	2.39e-06	4.17e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CAV1—breast cancer	2.38e-06	4.16e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—AKT1—breast cancer	2.38e-06	4.16e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.34e-06	4.09e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CD—breast cancer	2.31e-06	4.04e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CG—breast cancer	2.3e-06	4.02e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOA1—breast cancer	2.28e-06	3.98e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP19A1—breast cancer	2.24e-06	3.92e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—STK11—breast cancer	2.24e-06	3.92e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CA—breast cancer	2.2e-06	3.85e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NOS3—breast cancer	2.18e-06	3.81e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CG—breast cancer	2.17e-06	3.79e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—COMT—breast cancer	2.09e-06	3.65e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTP1—breast cancer	2.08e-06	3.63e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—AKT1—breast cancer	2.05e-06	3.59e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HMOX1—breast cancer	2.05e-06	3.58e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ITPR1—breast cancer	2.04e-06	3.57e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CD—breast cancer	2.02e-06	3.54e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CB—breast cancer	2.01e-06	3.52e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ALB—breast cancer	2e-06	3.49e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTGS2—breast cancer	1.99e-06	3.49e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ABCB1—breast cancer	1.97e-06	3.44e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TYMS—breast cancer	1.93e-06	3.38e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NOS3—breast cancer	1.91e-06	3.34e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOR1—breast cancer	1.91e-06	3.34e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.91e-06	3.34e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTM1—breast cancer	1.91e-06	3.34e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CD—breast cancer	1.91e-06	3.33e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ALB—breast cancer	1.88e-06	3.29e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GPX1—breast cancer	1.83e-06	3.2e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP1A1—breast cancer	1.81e-06	3.16e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NOS3—breast cancer	1.8e-06	3.15e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—AKT1—breast cancer	1.8e-06	3.15e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ERCC2—breast cancer	1.79e-06	3.14e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CB—breast cancer	1.76e-06	3.08e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTGS2—breast cancer	1.75e-06	3.05e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTEN—breast cancer	1.74e-06	3.04e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MTHFR—breast cancer	1.69e-06	2.95e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CB—breast cancer	1.66e-06	2.9e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTGS2—breast cancer	1.65e-06	2.88e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CAV1—breast cancer	1.56e-06	2.72e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTEN—breast cancer	1.52e-06	2.66e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTEN—breast cancer	1.44e-06	2.51e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CG—breast cancer	1.42e-06	2.48e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CD—breast cancer	1.25e-06	2.18e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALB—breast cancer	1.23e-06	2.15e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CA—breast cancer	1.23e-06	2.14e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NOS3—breast cancer	1.18e-06	2.06e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CB—breast cancer	1.09e-06	1.9e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTGS2—breast cancer	1.08e-06	1.88e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CA—breast cancer	1.07e-06	1.88e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CA—breast cancer	1.01e-06	1.77e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—AKT1—breast cancer	1e-06	1.75e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTEN—breast cancer	9.38e-07	1.64e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—AKT1—breast cancer	8.78e-07	1.53e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—AKT1—breast cancer	8.27e-07	1.45e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CA—breast cancer	6.62e-07	1.16e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—AKT1—breast cancer	5.41e-07	9.46e-06	CbGpPWpGaD
